Hase 1/2 Study of HS-10375 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
Status:
Recruiting
Trial end date:
2026-03-31
Target enrollment:
Participant gender:
Summary
HS-10375 is an oral, highly selective, small molecular inhibitor of EGFR C797S. This study
will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10375 in
Chinese advanced or metastatic NSCLC.